56 results about "Treated animal" patented technology

The present disclosure relates to flavor compositions and pet food products for preventing and / or treating chronic kidney disease (CKD) and / or urinary tract disease in an animal. In certain embodiments, the flavor compositions and pet food products have enhanced palatability.

The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. The composition has considerable curative effects on fungal infections on the skin surfaces of animals, with low toxicity and minimal irritation.

The invention relates to a veterinary hoof disease prevention and treatment composition as well as a preparation method and application thereof, and aims to solve the technical problems that existing commercial hoof bath lotion is limited in sterilization effect and relatively strong in local irritation, and a safe and efficient treatment medicament for treating cow hoof warts is lacked and the like. The invention provides a veterinary composition which comprises the following active ingredients: a glycyrrhizic acid compound, didecyl methyl ammonium bromide and polyhexamethylene guanidine salt, and the three components are combined, so that the composition has an antibacterial effect and an effect of promoting skin tissue repair at the same time. A series of tests prove that the traditional Chinese medicine composition can effectively inhibit animal pathogenic bacteria, prevent and / or treat animal limb and foot diseases and promote healing and repairing of ulcer injury. The medicament disclosed by the invention is suitable for preventing and treating limb and hoof diseases in a large-scale pasture, has the characteristics of high sterilization efficiency, good safety and effective treatment, and can improve the animal hoof health management level.

Embodiments described relate to a medical device including an invasive probe that, when inserted into an animal (e.g., a human or non-human animal, including a human or non-human mammal), may aid in diagnosing and / or treating a lesion of the animal (e.g., a growth or deposit within vasculature that fully or partially blocks the vasculature). The invasive probe may have one or more sensors to sense characteristics of the lesion, including by detecting one or more characteristics of tissues and / or biological materials of the lesion. The medical device may be configured to analyze the characteristics of a lesion and, based on the analysis, provide treatment recommendations to a clinician. Such treatment recommendations may include a manner in which to treat a lesion, such as which treatment to use to treat a lesion and / or a manner in which to use a treatment device.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, (I) wherein A1, A2, R1 and R2, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and / or treatment of an infection caused by pestivirus in an animal.

It is an object of the present invention to provide a composition for effectively preventing or treating Malassezia skin diseases.SOLUTION: The above problem can be solved by a composition for preventing or treating Malassezia dermatosis comprising citral of the present invention as an active ingredient, or a method for preventing or treating Malassezia dermatosis of an animal comprising a step of bringing an effective amount of citral into contact with the skin of an animal (excluding human).SELECTED DRAWING: None

The invention belongs to the field of biological pharmacy and animal medicine, and particularly relates to a nano antibody of antibacterial hair adhesin protein CfaE as well as a preparation method and application of the nano antibody. The invention provides a nano antibody mVHH-IgA of antibacterial hair adhesin protein CfaE, the nano antibody at least comprises a VHH fragment, the VHH fragment comprises three amino acid fragments of CDR1, CDR2 and CDR3, and the amino acid sequence of the CDR1-3 is shown as SEQ ID NO.1-3 in sequence, or the amino acid sequence of the CDR1-3 is shown as SEQ ID NO.4-6 in sequence, and the nano antibody mVHH-IgA of the antibacterial hair adhesin protein CfaE is prepared from the nano antibody mVHH-IgA of the antibacterial hair adhesin protein CfaE, the nano antibody mVHH-IgA of the antibacterial hair adhesin protein CfaE and the nano antibody mVHH-IgA of the antibacterial hair adhesin protein CfaE. Meanwhile, the VHH fragment is also fused with a secreting type IgA alpha chain constant region. The nano antibody mVHH-IgA provided by the invention has high specificity and stability, the nano antibody mVHH-IgA as a feed additive is mixed with a conventional feed to feed animals, and animal experiments show that the animal bacterial diarrhea can be effectively treated by feeding the feed containing the nano antibody mVHH-IgA provided by the invention.

There are provided a composition for preventing and treating heart disease due to pulmonary hypertension, and a functional preparation containing the same. The composition includes pimobendan, enalapril, torsemide, and spironolactone, and is thus effective in preventing and treating heart disease and pulmonary hypertension of animals.

The present invention relates to a composition for animals comprising a combination of one, two or more acid components and a binder. The binding agent comprises a tannin component and / or a polygalactose component. Further, the present invention relates to a composition for use as a pharmaceutical alternative, and in particular for use in the prevention and / or treatment of diarrhea in an animal. The invention also relates to the use of said composition for reducing the use of antibiotics and / or zinc oxide in animal breeding.

This application relates to compositions and methods used to treat animals with at least one microbial protein, such as a flagellin protein. In embodiments, application relates to compositions and methods to treat animals with a fusion protein comprising at least one adjuvant protein, such as a flagellin protein. In embodiments, the composition further includes at least one adjuvantic protein fused with at least one antigen protein, and the fusion protein is expressed in diatoms.

The disclosure relates to a sorting system for automatically selecting animals to be treated during a treatment period. A first aspect is a sorting system automatically selecting animals to be treated during a treatment period. The sorting system includes an automatic sort gate and a control arrangement receiving, via a user interface, user input indicative of sorting criteria applicable to animal properties and a maximum number of the animals allowed to be present simultaneously in the sorting area. The control arrangement is further configured to monitor a number of animals that enter and exit the sorting area. The control arrangement is finally configured to adjust one or more parameter values of the one or more sorting criteria, based on the monitored number of animals that enter and exit the sorting area. The disclosure also relates to a corresponding method and to a computer program for performing the method.

The invention provides a prevention and control method for cynomolgus monkeys based on SRV virus detection, and belongs to the technical field of cynomolgus monkey SRV virus detection, the cynomolgus monkeys after birth are subjected to intensive SRV antigen PCR and SRV antibody ELISA detection and are fed and managed in groups, negative animals after 9 months are subjected to annual quarantine, positive animals stop quarantine and are subjected to positive management by default, and the cynomolgus monkeys after birth are subjected to SRV antigen PCR detection and SRV antibody ELISA detection by default. The antibody positive and / or antigen positive belongs to the positive category. According to the method, SRV antigen PCR and SRV antibody ELISA detection are densely carried out on the cynomolgus monkeys after birth, grouping feeding management is carried out, early prevention and control can cut off a transmission chain, recessive infection can be effectively recognized, partially-infected monkeys are low in antibody reaction and even cannot be detected, but long-term detoxification can be achieved, recessive infection sources can be accurately removed by combining PCR and serological detection in the baby monkey period, and the method has the advantages of high specificity, high sensitivity, high sensitivity and the like. Although the detection cost is invested in the early stage, huge losses such as treatment, animal elimination and experiment repetition caused by disease outbreak in the future can be avoided.

The present disclosure provides veterinary formulations comprising rapamycin or rapalogs for administration to companion animals and methods of using the formulations to treat cardiac dysfunction, including hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, pressure-overload cardiac hypertrophy, cancer, effects of aging, inflammatory disease, and viral infection.

The invention relates to a drug composition for use in the treatment of diarrhea in animals, comprising a microbial enzyme solution, St. John's wort tea, vitamin B1, vitamin B6 and sodium benzoate as a preservative.

The present invention relates to a composition comprising a mixture of empty liposomes wherein the mixture of empty liposomes comprises: (a) a first empty liposome comprising cholesterol wherein the amount of cholesterol is at least 30% (weight / weight); and (b) a second empty liposome comprising sphingomyelin, for use in the treatment of sepsis, severe sepsis, septic shock or long-term and severe hypotension, preferably persistent hypotension, in an animal, preferably a human, for use in the treatment of hyperlipidemia in an animal, preferably a human. The present invention relates to a pharmaceutical composition for treating toxic shock syndrome in animals, preferably humans, or to the treatment of toxic shock syndrome in animals, preferably humans, or to the treatment of hypotension in acute lung injury, preferably said persistent hypotension, or to the treatment of toxic shock syndrome in animals, preferably humans, preferably septicaemia, severe septicaemia, acute respiratory distress syndrome, or to the treatment of hypotension in acute lung injury, preferably said persistent hypotension.

The present invention relates to topical pharmaceutical compositions comprising a corticosteroid and an insecticide selected from pyrethrin or a synthetic pyrethroid insecticide. Methods for their use in the treatment of allergic dermatitis, particularly hypersensitivity to insect bites, in animals using the compositions of the invention are also described.

The invention provides the tris salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidino]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid as a crystalline anhydrous or trihydrate; as well as polymorphs, pharmaceutical compositions, dosage forms and their use in the treatment of diseases, conditions or disorders regulated by the inhibition of an acetyl-CoA carboxylase (ACC) enzyme(s) in an animal.

The application belongs to the technical field of gene editing, and discloses a fusion protein, a base editor system for realizing protein multimerization and application. The fusion protein is a Cas9 protein with an embedded or replaced antigen epitope; the antigen epitope is an antigen epitope in a protein recruitment system; and the antigen epitope can realize multimerization of the fusion protein. The base editor system comprises the fusion protein and an editing enzyme fusion protein; the editing enzyme fusion protein comprises an antibody of the antigen epitope and an editing enzyme. The base editor system has the characteristics of a modular, multimerizable, programmable and expandable base editing platform, and brings more possibilities and selection capabilities to the field of gene editing. The base editor system can be applied to gene editing, including basic research, gene therapy, animal in vivo editing, agricultural breeding and other fields.

The present invention relates to vaccine compositions for treatment of substance use disorders, methods for the manufacture thereof, and methods for the use thereof to treat an animal. These compositions comprise a hapten conjugated via a linker to a protein scaffold and mixed with a particulate carrier and at least one immunostimulatory adjuvant molecule.

The present invention provides for enrichment of animal foodstuffs using endolysin polypeptides or fragments thereof, which possess antimicrobial activity (e g., against Clostridium septicum). 'The invention also provides for nucleic acid molecules encoding the endolysin, and methods of their production. Also provided are compositions comprising the endolysins, or comprising any of the means for producing the endolysin (e.g., a host cell, lysate, or dried product, etc.) that has antimicrobial activity, for the use of said compositions in a method of reducing the population of Clostridium septicum bacteria in a foodstuff, or preventing or treating a disease or disorder in an animal.

The disclosure provide for fusion proteins, multimeric proteins, and hexamer proteins capable of use for antibody discovery and / or therapeutic vaccination in companion animals, for example, dogs and cats. The disclosure further provides for multimeric and hexameric proteins capable of the treatment of pain, for example, inflammation, neuropathic pain, diabetes-related pain, arthritic pain and autoimmunity pain, as well as dermatological disorders, for example atopic dermatitis or pruritus, in animals. Use of multimeric and hexameric proteins described herein as vaccines or immunogen is further described.

Embodiments herein relate to engineered antimicrobial probiotics for the treatment of gastrointestinal tract pathogens. In an embodiment, a composition for treatment of an animal is included. The composition can include a first genetically engineered bacterium comprising a first exogenous polynucleotide. The first exogenous polynucleotide can include a first heterologous promoter and a first polynucleotide that encodes a first antimicrobial protein. The composition can also include a second genetically engineered bacterium comprising a second exogenous polynucleotide. The second exogenous polynucleotide can include a second heterologous promoter and a second polynucleotide that encodes a second antimicrobial protein. The first heterologous promoter can be induced by one set of exogenous environmental conditions found in the gastrointestinal tract of the animal and the second heterologous promoter can be induced by a second set of exogenous environmental conditions found in the gastrointestinal tract of the animal. Other embodiments are also included herein.

The present invention relates to an implant for insertion in a body lumen, wherein at least a portion of the surface is arranged to contact a wall of the body lumen and / or bodily fluid flowing through the lumen when the implant is inserted in the body lumen. The abovementioned portion of surface is covered with a surface sealing which is designed to dissolve within about 30 seconds when inserting the implant in the body lumen, such that this portion of surface is exposed to the body lumen. The present invention also relates to a method of manufacturing an implant as above described, comprising the steps of obtaining an implant with a surface; providing at least a portion of such surface with target characteristics; and covering such at least a portion of surface with a surface sealing to preserve the target characteristics. The present invention also refers to an implant set comprising an implant as defined and to a use of such an implant for treating an animal or a human body, wherein the treatment procedure comprises dissolving the surface sealing covering at least a portion of a surface of the implant by flushing the surface with a dissolving solution.

Provided in the present invention are a hepatitis B virus receptor OATP and the use thereof. Specifically, provided in the present invention is the use of a substance in the preparation of an agent for preventing and / or treating hepatitis B virus (HBV) and / or hepatitis D virus (HDV) infections in an animal or diseases related to said infections, wherein the substance prevents or reduces the interaction between HBV and / or HDV and an organic anion transporting polypeptide (OATP) in the animal, and / or prevents or reduces the expression and / or function of OATP in the animal. Further provided in the present invention are a cell model and an animal model having susceptibility to HBV and / or HDV that are obtained by means of transferring an exogenous SLCO gene into a cell or expressing an exogenous OATP protein, and a method for establishing the models; a method for delivering a drug by means of targeting OATP, and a drug delivery vehicle targeting OATP; and an OATP-targeted delivery polypeptide vehicle derived from a hepadnaviridae surface antigen.

The invention discloses a method for surface modification of a biological material and a modified pericardium material, and relates to the technical field of biomedical materials. The method comprises the following steps: S1, providing an animal pericardium material subjected to glutaraldehyde crosslinking treatment; providing a bridging molecule comprising a first bridging group and a second bridging group, and a phosphorylcholine polymer terminal-modified with a third bridging group; combining the first bridging group with the aldehyde group on the surface of the pericardium material through a first covalent reaction; combining the second bridging group with the third bridging group through a second covalent reaction to realize grafting of the phosphorylcholine polymer on the surface of the material; the first covalent reaction and / or the second covalent reaction comprise Schiff base formation and reductive amination processes. According to the prepared modified pericardium material, the phosphorylcholine bionic coating is introduced, the surface blood compatibility of the material can be improved, blood coagulation system activation and platelet adhesion can be reduced, deposition starting of calcium ions on the surface of the material can be inhibited, and safety is high.

Immunomodulatory compounds of Formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof are defined herein; and compositions comprising the compounds are provided, wherein R 0 , R 1 , R 2 , R 10 , W, ring C, and n are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof. The present application also includes methods for treating an inflammatory and / or immune disease or disorder in an animal by administering a therapeutically effective amount of a compound of Formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof; or use of the compounds of Formula (1) for the manufacture of a medicament for treating an inflammatory and / or immune disease or disorder in an animal.

The invention discloses a traditional Chinese medicine composition for treating animal gout and application of the traditional Chinese medicine composition, and belongs to the technical field of animal medicine. The core active components of the traditional Chinese medicine composition comprise astilbin, tanshinone IIA and tetrahydrocurcumin, wherein the preferable mass ratio of all the components is 4: 1: 3. Pharmacodynamic studies show that the composition has a significant synergistic effect, can effectively reduce the blood uric acid level of animals with hyperuricemia, and synergistically inhibits the activity of xanthine oxidase (XOD). Compared with existing chemical drugs, the pharmaceutical composition disclosed by the invention has the advantages that through synergistic combination of the drugs, the toxic and side effects and the possibility of drug resistance are effectively reduced while the concentration of uric acid is efficiently reduced, a safe, efficient and economic brand-new scheme is provided for treating animal gout, and the pharmaceutical composition has important application value.

Provided herein are probiotic compositions and methods for treating animals or humans, or human or animal feed, or a surface in contact therewith comprising: feeding or providing a feed, supplement, additive, or food to animals or humans with a composition comprising one or more probiotic bacteria, supernatant, extract, broth, or fermentate thereof, selected from L28, L3AL3 A, L20-B, J7, J14, J27, J43, J16, J34, J25, L5-A and J19 provided in an amount sufficient to be at least one of: bactericidal against bacteria selected from at least one of: spore-forming bacteria, gram positive bacteria, gram negative bacteria, or combinations thereof, in animal or human intestines, improve gut structure, reduce gut inflammation, improved nutrient digestibility, improve mineral absorption and growth performance, reduce carriage, reduce fecal shedding, or reduce gut infection and inflammation.